Breast Cancer Research and Treatment最新文献

{"title":"Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.","authors":"Marziyeh Ghorbani, Soha Namazi, Mehdi Dehghani, Farideh Razi, Bahman Khalvati, Ali Dehshahri","doi":"10.1007/s10549-025-07674-x","DOIUrl":"10.1007/s10549-025-07674-x","url":null,"abstract":"<p><strong>Purpose: </strong>Recent studies have shown that the truncated isoform of the neurokinin-1 receptor (NK-1R) and its ligand, substance P (SP), are overexpressed in tumor cells playing a crucial role in chemoresistance, leading to proliferation, angiogenesis, and metastasis. Hence, this study aims to assess if the polymorphisms of the NK-1R-encoding gene influence the truncated NK-1R level, chemoresistance, and pathological complete response (pCR) achievement in breast cancer patients.</p><p><strong>Methods: </strong>The real-time PCR-HRMA was performed to genotype TACR1 eighteen tag SNPs in 153 neoadjuvant chemotherapy-receiving breast cancer patients. Univariate analysis was performed to assess the association of baseline and tumor characteristics with pCR achievement. The association of each variant and pCR achievement was assessed by executing logistic regression while adjusting for covariates and correcting for multiple tests using permutation.</p><p><strong>Results: </strong>The probability of pCR to neoadjuvant chemotherapy is higher for patients with tumor grade-III as well as stage-I. Assuming the additive, dominant, or recessive models, rs17010664, rs6715729, and rs3771869 were significantly associated with pCR achievement.</p><p><strong>Conclusion: </strong>Positioned close to the truncation-occurring region, belonging to an exon-splicing enhancer motif, the rs17010664 C allele seems to play a crucial role in enhancing the TACR1 last exon splicing leading to increased truncated NK-1R production, chemoresistance, and decreased pCR achievement. Accordingly, The SP/truncated NK-1R axis blockade by NK-1R antagonists seems to be a therapeutic approach to overcoming chemoresistance and achieving pCR in the rs17010664 risk-allele-bearing patients. Hence, conducting further studies to determine the required dose of NK-1R antagonists, repurposed as an antitumor agent, is favored.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"617-626"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National trends and survival outcomes associated with non-guideline-concordant treatment of inflammatory breast cancer.","authors":"Elsa A Kronen, Nikhil L Chervu, Ayesha P Ng, Hanjoo Lee, Peyman Benharash, Carlie K Thompson","doi":"10.1007/s10549-025-07669-8","DOIUrl":"10.1007/s10549-025-07669-8","url":null,"abstract":"<p><strong>Purpose: </strong>National Comprehensive Cancer Network (NCCN) guidelines for inflammatory breast cancer (IBC) recommend trimodal therapy: neoadjuvant chemotherapy, modified radical mastectomy (MRM), and adjuvant radiation therapy. Historically, a minority received NCCN-guideline-concordant trimodal therapy (GCT). We explored factors associated with non-concordance, types of non-concordance, and the association of GCT with survival.</p><p><strong>Methods: </strong>The National Cancer Database (NCDB) was analyzed for patients with non-metastatic IBC who underwent surgery from 2006 to 2019. Multivariate logistic regression identified factors associated with GCT. Cox proportional hazard models assessed the impact of GCT, and components of non-concordance, on mortality.</p><p><strong>Results: </strong>Of 13,733 patients, 47.6% received GCT. Of non-GCT patients, 39.7% had mixed non-concordance, 25.5% exclusive chemotherapy non-concordance, 24.0% exclusive radiation non-concordance, and 10.8% exclusive surgical non-concordance. A higher burden of comorbidities, node-negative disease, and positive human epidermal growth factor receptor 2 (HER2) and hormone receptor status were associated with reduced odds of receiving GCT. GCT was associated with reduced 3-(hazard ratio [HR] = 0.83, 95% CI 0.73-0.95) and 5-year (HR = 0.83, 95% CI 0.76-0.91) mortality. Chemotherapy non-concordance and mixed non-concordance were associated with higher three-(HR = 1.28, 95% CI 1.07-1.53; HR = 1.20, 95% CI 1.01-1.43 respectively) and 5-year (HR = 1.42, 95% CI 1.26-1.60; HR = 1.17, 95% CI 1.03-1.33) mortality. Radiation non-concordance was associated with increased hazard of 1-year mortality (HR = 3.03, 95% CI 1.75-5.23). Exclusive surgical non-concordance was not associated with survival; however, simple mastectomy portended a higher hazard of 5-year mortality (HR = 1.26, 95% CI 1.08-1.46).</p><p><strong>Conclusion: </strong>Despite improved survival, a minority of patients received GCT. Omitting neoadjuvant chemotherapy or adjuvant radiation was associated with reduced survival, whereas surgical non-concordance in patients with concordant chemoradiation did not impact survival. Simple mastectomy was associated with reduced survival, supporting the rationale for axillary lymphadenectomy.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"527-535"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning can reliably predict malignancy of breast lesions based on clinical and ultrasonographic features.","authors":"I P C Buzatto, S A Recife, L Miguel, R M Bonini, N Onari, A L P A Faim, L Silvestre, D P Carlotti, A Fröhlich, D G Tiezzi","doi":"10.1007/s10549-024-07429-0","DOIUrl":"10.1007/s10549-024-07429-0","url":null,"abstract":"<p><strong>Purpose: </strong>To establish a reliable machine learning model to predict malignancy in breast lesions identified by ultrasound (US) and optimize the negative predictive value to minimize unnecessary biopsies.</p><p><strong>Methods: </strong>We included clinical and ultrasonographic attributes from 1526 breast lesions classified as BI-RADS 3, 4a, 4b, 4c, 5, and 6 that underwent US-guided breast biopsy in four institutions. We selected the most informative attributes to train nine machine learning models, ensemble models and models with tuned threshold to make inferences about the diagnosis of BI-RADS 4a and 4b lesions (validation dataset). We tested the performance of the final model with 403 new suspicious lesions.</p><p><strong>Results: </strong>The most informative attributes were shape, margin, orientation and size of the lesions, the resistance index of the internal vessel, the age of the patient and the presence of a palpable lump. The highest mean negative predictive value (NPV) was achieved with the K-Nearest Neighbors algorithm (97.9%). Making ensembles did not improve the performance. Tuning the threshold did improve the performance of the models and we chose the algorithm XGBoost with the tuned threshold as the final one. The tested performance of the final model was: NPV 98.1%, false negative 1.9%, positive predictive value 77.1%, false positive 22.9%. Applying this final model, we would have missed 2 of the 231 malignant lesions of the test dataset (0.8%).</p><p><strong>Conclusion: </strong>Machine learning can help physicians predict malignancy in suspicious breast lesions identified by the US. Our final model would be able to avoid 60.4% of the biopsies in benign lesions missing less than 1% of the cancer cases.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"581-593"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of radiofrequency identification tag placement: can early placement save time and patient experience?","authors":"Ashley M Newman, Abigail E Daly, Kyle J Anderman, Pragya A Dang, Anvy T Nguyen, Barbara L Smith, Michele A Gadd, Michelle C Specht","doi":"10.1007/s10549-025-07681-y","DOIUrl":"10.1007/s10549-025-07681-y","url":null,"abstract":"<p><strong>Purpose: </strong>Radiofrequency identification tag localization (TL) is a method of localizing nonpalpable breast cancers and high-risk lesions that can be performed prior to the day of surgery (DOS). We evaluated if placement of TL prior to DOS would affect patients' length of stay (LOS) and improve surgical on-time starts.</p><p><strong>Methods: </strong>A retrospective review of excisional biopsies and lumpectomies with TL was performed. Associations between timing of TL (DOS vs. prior), time in radiology, surgical case delay, LOS on DOS, and total LOS were assessed.</p><p><strong>Results: </strong>439 patients underwent TL for nonpalpable breast cancer or high-risk lesions between July 2018 and July 2021 at our institutions. 158 TL procedures were performed on the DOS and 281 TL procedures were performed a median of 3 days prior to the DOS (range 1-28). All intended targets were removed. The median total LOS (time in radiology and surgery) was 336 min and 434 min for the early placement group and DOS group, respectively (p < 0.001). The median length of time in radiology was 47 min for the early placement group and 54 min for the DOS group (p < 0.001). Cases were significantly more likely to be delayed (p = 0.002) and could not be first-start cases if TL was performed on DOS. Vasovagal events during TL and narcotic use in the post-operative setting were rare across both groups.</p><p><strong>Conclusions: </strong>TL prior to DOS was associated with a decrease in total LOS (p < 0.001) and case delay (p = 0.002), as well as an increase in first-start cases. These findings suggest the potential superiority of TL prior to DOS.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"669-674"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting \"don't eat me\" signal: breast cancer immunotherapy.","authors":"Yue Gao, Xiaoyan Zhang, Mingqiang Ding, Zhenkun Fu, Lei Zhong","doi":"10.1007/s10549-025-07659-w","DOIUrl":"10.1007/s10549-025-07659-w","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer ranks as the most prevalent cancer type impacting women globally, both in terms of incidence and mortality rates, making it a major health concern for females. There's an urgent requirement to delve into new cancer treatment methods to improve patient survival rates.</p><p><strong>Methods: </strong>Immunotherapy has gained recognition as a promising area of research in the treatment of breast cancer, with targeted immune checkpoint therapies demonstrating the potential to yield sustained clinical responses and improve overall survival rates. Presently, the predominant immune checkpoints identified on breast cancer cells include CD47, CD24, PD-L1, MHC-I, and STC-1, among others. Nevertheless, the specific roles of these various immune checkpoints in breast carcinogenesis, metastasis, and immune evasion have yet to be comprehensively elucidated. We conducted a comprehensive review of the existing literature pertaining to breast cancer and immune checkpoint inhibitors, providing a summary of findings and an outlook on future research directions.</p><p><strong>Results: </strong>This article reviews the advancements in research concerning each immune checkpoint in breast cancer and their contributions to immune evasion, while also synthesizing immunotherapy strategies informed by these mechanisms. Furthermore, it anticipates future research priorities, thereby providing a theoretical foundation to guide immunotherapy as a potential interventional approach for breast cancer treatment.</p><p><strong>Conclusion: </strong>Knowledge of immune checkpoints will drive the creation of novel cancer therapies, and future breast cancer research will increasingly emphasize personalized treatments tailored to patients' specific tumor characteristics.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"277-292"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer.","authors":"Ezgi Turkoglu, Goncagul Akdag Topal, Sedat Yildirim, Oguzcan Kinikoglu, Nisanur Sariyar Busery, Miray Aydogan, Hacer Sahika Yildiz, Seval Orman, Ayberk Bayramgil, Tugce Kubra Gunes, Mustafa Alperen Tunc, Nargiz Majidova, Deniz Isik, Sermin Kokten, Hatice Odabas, Nedim Turan","doi":"10.1007/s10549-025-07694-7","DOIUrl":"https://doi.org/10.1007/s10549-025-07694-7","url":null,"abstract":"<p><strong>Background: </strong>Dual HER2 blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy improves outcomes in HER2-positive breast cancer. The optimal taxane backbone (paclitaxel vs. docetaxel) remains unclear.</p><p><strong>Methods: </strong>This retrospective study included 220 HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by dual HER2 blockade with trastuzumab, pertuzumab, and either paclitaxel (80 mg/m² for 12 weeks) or docetaxel (75 mg/m² every three weeks for four cycles). Pathological complete response (pCR), disease-free survival (DFS), overall survival (OS), and toxicity profiles were analyzed.</p><p><strong>Results: </strong>At the time of diagnosis, 6% of the patients included in the study were at stage I, 70.4% were at stage II, and 23.6% were at stage III. The overall pCR rate was 55%, with no significant difference between the paclitaxel (57.9%) and docetaxel (52.2%) groups (p = 0.418). Higher pCR rates were associated with grade 3 tumors, ER/PR negativity, and Ki- 67 ≥ 20%. Patients achieving pCR had significantly lower relapse rates (2.5% vs. 16.2%, p < 0.001). These factors were significantly associated with pCR in univariate analysis but did not remain independent predictors in multivariate analysis. DFS and OS were higher in the paclitaxel group compared to the docetaxel group (DFS: 96.3% vs. 83.2%, p = 0.025; OS: 100% vs. 95.5%, p = 0.042). Grade 3-4 anemia was more frequent with docetaxel (23% vs. 9%, p = 0.007).</p><p><strong>Conclusion: </strong>Both paclitaxel and docetaxel are effective in neoadjuvant dual HER2 blockade regimens. Paclitaxel demonstrated better DFS, OS, and a favorable safety profile, supporting its use as a preferred option.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"211 3","pages":"743-752"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stable overexpression of the epithelial sodium channel alpha subunit reduces migration and proliferation in breast cancer cells.","authors":"Sarah R A McQueen, Wey Qi Chin, Heather E Cunliffe, Fiona J McDonald","doi":"10.1007/s10549-025-07667-w","DOIUrl":"https://doi.org/10.1007/s10549-025-07667-w","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most common cancer diagnosed in women worldwide. Ion channels have emerged as novel regulators of cancer cell functions, including proliferation and migration. The epithelial sodium channel (ENaC) has a key role in blood pressure regulation, and ENaC levels affect the characteristics of several types of cancer. In breast cancer, a role for αENaC has not been investigated in migration previously nor the effect of stable overexpression of αENaC on proliferation.</p><p><strong>Methods: </strong>Correlations of the mRNA levels for the four ENaC subunits and breast cancer survival outcomes were assessed in publicly available data and the association between αENaC and migration-related genes. Three isogenic monoclonal derivatives of MDA-MB-231 breast cancer cell lines were created with stable αENaC overexpression. Migration assays (scratch wound assay and Boyden chamber assays) and a proliferation assay (EdU) were used to determine the effect of αENaC overexpression compared to control MDA-MB-231 cells.</p><p><strong>Results: </strong>Higher α- or δENaC expression was correlated with improved patient survival. Higher αENaC expression correlated with lower expression of migration-associated genes. Stable overexpression of αENaC in MDA-MB-231 cells resulted in reduced in vitro migration and proliferation of all three clones compared to parental control cells.</p><p><strong>Conclusion: </strong>Higher αENaC expression correlates with improved patient outcomes, and overexpression in breast cancer cells reduces both cell migration and proliferation. These results highlight the possibility of ENaC as a target for future breast cancer treatments.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"211 3","pages":"595-604"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study.","authors":"Kunal Ramesh Chandekar, Swayamjeet Satapathy, Yamini Dharmashaktu, Sanjana Ballal, Piyush Ranjan, Atul Batra, Ajay Gogia, Sandeep Mathur, Chandrasekhar Bal","doi":"10.1007/s10549-025-07651-4","DOIUrl":"10.1007/s10549-025-07651-4","url":null,"abstract":"<p><strong>Purpose: </strong>Somatostatin receptor (SSTR) expression has been reported in estrogen receptor-positive (ER +) metastatic breast cancer (mBC) by pathology and immunohistochemistry studies. We aimed to investigate whether SSTR could be a viable target for PET imaging and potential theranostics in ER + mBC.</p><p><strong>Methods: </strong>Thirty prospectively recruited patients with ER + mBC underwent PET/CT imaging with [¹⁸F]FDG and [⁶⁸Ga]Ga-DOTATATE (within three weeks). Detection rates (per-patient, per-region), number of lesions detected, SUVmax values, Krenning scores, SSTR-FDG visual scores, and PET-based staging with both radiotracers were compared.</p><p><strong>Results: </strong>[¹⁸F]FDG and [⁶⁸Ga]Ga-DOTATATE PET/CT had similar per-patient detection rates (100% vs 96.7%, P = 1.0). Per-region and per-lesion analyses revealed comparable detection of local/breast lesions, nodal, and skeletal metastases. However, [¹⁸F]FDG outperformed [⁶⁸Ga]Ga-DOTATATE in detecting visceral/other metastases (235 vs 128 lesions, P = 0.003). [⁶⁸Ga]Ga-DOTATATE resulted in a lower PET-based M-stage compared to [¹⁸F]FDG in 10% of patients, although T-/N-stages were concordant in all patients. HER2- patients showed a trend of higher [⁶⁸Ga]Ga-DOTATATE lesional SUVmax values compared to the HER2 + sub-group (median 9.0 vs 3.8, P = 0.078). 3/30 (10%) participants had a patient-level Krenning score ≥ 3 ([⁶⁸Ga]Ga-DOTATATE uptake higher than liver background in majority of the lesions), potentially making them suitable for SSTR-targeted radionuclide therapy.</p><p><strong>Conclusions: </strong>SSTR-targeted theranostics may represent a novel potential alternative in a subset of patients with ER + mBC. Its generalized applicability is limited by poor sensitivity for visceral metastases and significant inter-lesion heterogeneity. Future studies must identify how tumor subtype, proliferation, and prior systemic therapies impact SSTR expression levels in these patients to ensure meaningful clinical translation.</p><p><strong>Clinical trial registration: </strong>Clinical Trials Registry-India: CTRI/2023/03/051025 (prospectively registered on 23.03.2023).</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"363-373"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of breast cancer risk after breast density notification in a population-based screening program.","authors":"Dorinda 't Hart, Ross Marriott, Jennifer Stone","doi":"10.1007/s10549-025-07662-1","DOIUrl":"10.1007/s10549-025-07662-1","url":null,"abstract":"<p><strong>Background: </strong>Despite increasing evidence to support risk-based breast cancer screening, individuals' understanding of personal risk is not well understood. This study compares women's perceptions of risk to their estimated risk, and examines factors associated with perceived risk, including breast density notification, within a population-based screening program.</p><p><strong>Methods: </strong>A survey of 5784 women measured their perceived risk via three questions: a number from 0 to 100 (numeric), a category from very low to very high (verbal), a comparative category relative to an average woman (comparative). Descriptive analyses assessed correlations between perceived risk variables and estimated risk (using the Gail Model), and modelled relationships using K-fold cross-validation. A Graded Response Model was used to obtain an index of unobserved (latent) overall perceived risk from the three questions. Multivariable modelling was used to investigate factors associated with overall perceived risk.</p><p><strong>Results: </strong>Most participants perceived themselves as being at neither high nor low risk, although perceived risk was higher than estimated risk, on average. All three perceived risk measures were positively correlated with each other and with estimated risk. Overall perceived risk was weakly associated with estimated risk (adjusted R² = 0.12). Women who received multiple breast density notifications, were younger, or had a family history, perceived their risk as higher relative to respective reference groups. Those who identified as Asian perceived their risk as lower than those who identified as European/Caucasian.</p><p><strong>Conclusion: </strong>Individuals' understanding of breast cancer risk is poor. New strategies are needed to improve education and awareness of personal risk.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"455-465"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.","authors":"Nour Maher Mustafa, Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Hamza Muneer Alakhras, Anas Saed Abed, Sereen Ahmad Bani-Said, Laith Sami Othman, Areen Shdaifat","doi":"10.1007/s10549-025-07737-z","DOIUrl":"https://doi.org/10.1007/s10549-025-07737-z","url":null,"abstract":"<p><strong>Background: </strong>Hormone receptor-positive (HR+) breast cancer continues to be a significant global challenge, as resistance to endocrine therapy (ET) often reduces its effectiveness. Entinostat (ENT), a novel and selective histone deacetylase inhibitor (HDACi), has been suggested to overcome the resistance. However, there is still ongoing debate regarding its efficacy and safety.</p><p><strong>Objective: </strong>Our meta-analysis aims to assess the efficacy and safety of ENT plus exemestane (EXE) versus placebo (PL) plus EXE in patients with HR+ breast cancer.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a systematic search was conducted across PubMed, Web of Science, and Cochrane Library up to November 2024, resulting in the inclusion of four randomized controlled trials (RCTs) involving 1371 patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS), while secondary outcomes were the objective response rate (ORR), clinical benefit rate (CBR), and adverse events (AEs). Our meta-analysis was prospectively registered in PROSPERO (registration number: CRD42024615056).</p><p><strong>Results: </strong>Our Analysis showed that ENT + EXE significantly enhanced PFS in the overall HR+ population Hazard Ratio (HR) = 0.79 (95% CI 0.68-0.92; P = 0.003), particularly among human epidermal growth factor receptor-2 (HER2-) negative patients (HR = 0.80; 95% CI 0.68-0.95; P = 0.01) when compared to PL + EXE. However, no significant improvements were noted in OS (HR = 0.91; 95% CI 0.63-1.30; P = 0.60), ORR with relative risk (RR) = 1.37 (95% CI 0.90-2.07; P = 0.14), CBR (RR = 1.15; 95% CI 0.89-1.74; P = 0.29). Furthermore, our safety analysis demonstrated that patients receiving ENT + EXE experienced significantly higher rates of adverse events (AEs) of all grades, with a RR of 1.33 (95% CI 0.99-1.78) and a significant increase in grade ≥ 3 AEs (RR = 3.04; 95% CI 2.52-3.67).</p><p><strong>Conclusion: </strong>The ENT + EXE combination demonstrates significant PFS benefits in HR + breast cancer patients compared to PL + EXE. However, no improvements were seen in OS, ORR, or CBR. In addition, the higher incidence of AEs, especially hematologic and gastrointestinal, highlights the need for careful patient selection and monitoring.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}